专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

41. 发明申请

US20220000982A1 GIP DERIVATIVES AND USES THEREOF 有权
公开(公告)号：US20220000982A1
公开(公告)日：2022-01-06
申请号：US17052702
申请日：2019-05-03
申请人： Novo Nordisk A/S
发明人： Wouter Frederik Johan Hogendorf , Henning Thoegersen , Nicholas Raymond Cox , Patrick J. Knerr , Richard Dimarchi , Brian Finan , Jesper F. Lau , Steffen Reedtz-Runge , Fa Liu
IPC分类号： A61K38/22 , C07K14/645 , A61K38/26 , A61P3/10
摘要： The present invention relates to novel peptides that are derivatives of glucose-dependent insulinotropic polypeptide (GIP) analogues having improved physical stability in solution and a protracted profile of action. More particular the invention relates to such peptides that are agonists at the GIP receptor and to their use in weight management or for treatment of diseases such as obesity, diabetes or non-alcoholic steatohepatitis (NASH).

42. 发明授权

US11208452B2 Insulins with polar recombinant extensions 有权
公开(公告)号：US11208452B2
公开(公告)日：2021-12-28
申请号：US15577990
申请日：2016-06-02
申请人： Novo Nordisk A/S
发明人： Thomas Boerglum Kjeldsen , Thomas Hoeg-Jensen , Tine Nygaard Vinther , Frantisek Hubalek , Ingrid Pettersson
IPC分类号： C07K14/62 , A61P3/10 , A61K38/00
摘要： The present invention relates to novel insulins or insulins analogues that are extended with predominantly sequences of polar amino acid residues in order to improve the half-life and stability of the drug substance. The invention also provides pharmaceutical compositions comprising such drug substances, and relates to the use of such drug substances for the treatment or prevention of medical conditions relating to diabetes.

43. 发明申请

US20210361919A1 QUICK RELEASE CAPSULES 有权
公开(公告)号：US20210361919A1
公开(公告)日：2021-11-25
申请号：US17055905
申请日：2019-05-17
申请人： Massachusetts Institute of Technology , The Brigham and Women's Hospital, Inc. , Novo Nordisk A/S
发明人： Robert S. Langer , Carlo Giovanni Traverso , Alex G. Abramson , David Dellal , Christoph Winfried Johannes Steiger , Niclas Roxhed , Ester Caffarel Salvador , Vance Soares , Daniel Minahan , Morten Revsgaard Frederiksen
IPC分类号： A61M31/00 , A61M37/00
摘要： Articles for rapid release of components including, for example, quick release capsules, are generally provided. Advantageously, in some embodiments, the articles described herein may be configured to prevent fluid from contacting a component h contained therein (e.g., tissue interfacing component) or payload contained therein until a desired time, e.g., the time at which the component is configured to release from the article to a location internal to a subject (e.g., localize to a tissue wall in the subject). In some embodiments, the article comprises a first compartment and a second compartment not in fluid communication with the first compartment. In some embodiments, the first compartment and second compartment are fluidically isolated. For example, in some cases, the first compartment comprises a mechanism for releasing a component contained within the article and the second compartment comprises the component.

44. 发明申请

US20210346606A1 SYRINGE DEVICE WITH A DOSE LIMITING MECHANISM AND AN ADDITIONAL SAFETY MECHANISM 有权
公开(公告)号：US20210346606A1
公开(公告)日：2021-11-11
申请号：US17382508
申请日：2021-07-22
申请人： Novo Nordisk A/S
发明人： Jacob Eiland , Christian Peter Enggaard , Claus Schmidt Moeller , Tom Hede Markussen
IPC分类号： A61M5/315 , A61M5/20
摘要： A syringe device for ejecting a dose of a medicament, the syringe device comprising: a dose limiting mechanism arranged to interact with a dose ejecting mechanism to prevent ejection of a dose exceeding a set dose, and a safety mechanism, which is arranged such with respect to the dose ejecting mechanism that, if the dose limiting mechanism fails, the safety mechanism prevents ejection of a dose exceeding the set dose.

45. 发明申请

US20210346594A1 MEDICAL INJECTION DEVICE WITH A CLEANING CHAMBER 有权
公开(公告)号：US20210346594A1
公开(公告)日：2021-11-11
申请号：US17382536
申请日：2021-07-22
申请人： Novo Nordisk A/S
发明人： Mie Haraldsted , Morten Revsgaard Frederiksen , Matias Melander , Christian Hoejris Nielsen , Graham Hinde , Bas Kamp , Roshan Hakkim
IPC分类号： A61M5/00 , A61M5/32 , A61M5/315 , A61M5/28
摘要： The invention relates to an injection device for injecting a liquid drug. The injection device comprises a housing assembly supporting a non-removable cartridge having an interior chamber containing the liquid drug to be injected and a reusable needle cannula connected to the cartridge. A needle shield assembly provided with a cleaning chamber containing a volume of a cleaning agent for cleaning at least the distal tip of the needle cannula between subsequent injections is further provided. The needle shield assembly is axially movable in a proximal direction in relation to the housing assembly from a first position to a second position upon rotation of at least a part of the needle shield assembly, wherein the first position is a position in which the distal tip of the needle cannula is located inside the cleaning chamber thereby cleansing the distal tip of the needle cannula, and the second position is a position in which the distal tip of the needle cannula is located outside and distal to the cleaning chamber for equalizing the pressure in the cartridge.

46. 发明申请

US20210338933A1 AUTOINJECTION DEVICE HAVING DOSE LOGGING 有权
公开(公告)号：US20210338933A1
公开(公告)日：2021-11-04
申请号：US17261730
申请日：2019-07-17
申请人： Novo Nordisk A/S
发明人： Nikolaj Eusebius Jakobsen
IPC分类号： A61M5/20 , A61M5/315
摘要： An autoinjection device (10′) for expelling a dose of drug is described. A housing (300) movably holds a power unit (400, 500, 550, 700) configured for driving the piston of a held container (100), the power unit comprising: a) a plunger (500) comprising a retaining geometry (515), b) a drive spring (550) arranged in a tensed state wherein a first end portion of the drive spring (550) provides a distally directed force on the plunger (500), and c) a power base (400) operably coupled to the drive spring (550) and the plunger (500), the power base (400) grounding a second end portion of the drive spring (550), wherein, in a pre-firing state of the autoinjector, a retaining element (410, 415) of the power base (400) releasably engages the retaining geometry (515) of the plunger to retain the plunger against the force of the drive spring (550), wherein the autoinjection device (10′) further defines a user operable trigger element (700) cooperating with the retaining element (410, 415) to maintain retaining engagement with the retaining geometry (515) of the plunger until triggering, and further defines an electronic module (80′) comprising a sensor (850, 851) configured to sense the shift of position of the power base (400) as it moves upon triggering.

47. 发明授权

US11123296B2 Compositions comprising a delivery agent and preparation thereof 有权
公开(公告)号：US11123296B2
公开(公告)日：2021-09-21
申请号：US16409151
申请日：2019-05-10
申请人： Novo Nordisk A/S
发明人： Thomas Vilhelmsen
IPC分类号： A01N25/12 , A61K9/16 , A61K9/20 , A61K38/26
摘要： The invention relates to granules and pharmaceutical compositions comprising a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant obtained by mixing hereof for more than 5 minutes prior to granulation as well as processes for their preparation and use thereof in medicine.

48. 发明申请

US20210275749A1 Drug delivery device 有权
公开(公告)号：US20210275749A1
公开(公告)日：2021-09-09
申请号：US17327173
申请日：2021-05-21
申请人： Novo Nordisk A/S
发明人： Henrik Bengtsson , Anders Noerbygaard , Ronan Carroll , Emil Gram Spork
IPC分类号： A61M5/31 , A61M5/315
摘要： The present invention relates to a drug delivery device for expelling a dose of drug from a held cartridge and that defines a distal drug outlet end and an opposite proximal end. The drug delivery device comprises: a distal housing component (110) holding a cartridge (113) comprising a liquid drug and a piston slideable arranged therein in an axial direction, and a proximal housing component (101) housing a dose setting and expelling mechanism comprising a piston rod for exerting a force on the piston of the cartridge (113) in a distal direction for expelling a dose. The distal housing component (110) and the proximal housing component (101) are displaceably arranged in axial direction relative to each other for reducing an axial distance between the piston rod (120) and the piston of the cartridge (113). One of the distal housing component (110) and the proximal housing component (101) comprises a threaded adjustment component (103) being held at an axial fixed location on said one of the distal housing component (110) and the proximal housing component (101) and defining a first thread (103b) being in threaded engagement with a second thread (110b) defined by the other of the distal housing component (110) and the proximal housing component (101). After displacement the threaded adjustment component (103) is rotatably fixated so that the adjustment component (103) cannot be rotated without the use of a tool.

49. 发明申请

US20210260275A1 MULTI-USE DRUG DELIVERY DEVICE FOR DRUGS WITH INSUFFICINET LEVEL OF PRESERVATIVES 有权
公开(公告)号：US20210260275A1
公开(公告)日：2021-08-26
申请号：US17251255
申请日：2019-06-03
申请人： Novo Nordisk A/S
发明人： Henrik Bengtsson , Vera Pinto Glenting , Joern Drustrup
IPC分类号： A61M5/00 , A61M5/28 , A61M5/315 , A61M5/32
摘要： A multi-use injection device (100) for multiple subcutaneous injections, wherein the injection device comprises a device main portion (110) and a multi-use needle unit (150) adapted to prevent unintended introduction of living microorganisms into a reservoir (114) of the device main portion during use of the injection device, and thereby promote bacteriostasis of a multiple-use drug preparation (115) during a use period with multiple injections. The drug delivery device (100) is adapted to enable multiple injections, without accidentally introducing living microbial contaminations into the reservoir during use, by adapting the multi-use needle to: (i) sterilize contaminations introduced into the distal needle after each exposure of a distal injection needle (156), (ii) restrict diffusion and flow from the distal needle (156) to the reservoir (114) with a valve (170), (iii), and by allowing the needle unit to remain mounted in the in-use configuration during the use period with multiple injections.

50. 发明申请

US20210236601A1 Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid 有权
公开(公告)号：US20210236601A1
公开(公告)日：2021-08-05
申请号：US17053511
申请日：2019-05-06
申请人： Novo Nordisk A/S
发明人： Simon Bjerregaard , Ulrik Lytt Rahbek , Philip Jonas Sassene , Jorrit Jeroen Water , Andreas Vegge
IPC分类号： A61K38/26 , A61K47/22 , A61K47/10 , A61K47/18 , A61K9/00 , A61K47/14
摘要： The invention relates to pharmaceutical compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid. The invention further relates to processes for the preparation of such compositions, and their use in medicine.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式